Darshan Kulkarni

Oct 7, 2024 | businesslawtoday.org | Shawn Garrett |Acquisitions Law |Darshan Kulkarni |Chauncey M. Lane

CURRENT MONTH (September 2024)Delaware Chancery Court Issues Ruling on Earnout Dispute: Did Alexion’s Efforts Meet ‘Commercially Reasonable’ Standard in Syntimmune Merger? By Shawn Garrett, Garrett, PLLCOn September 5, 2024, the Delaware Court of Chancery issued a memorandum opinion and judgment on a case relating to a disputed earnout in a post-merger entity based on milestones contemplated in the merger agreement. In Shareholder Representative Services, LLC., v. Alexion Pharmaceuticals, Inc.

Sep 18, 2024 | businesslawtoday.org | Darshan Kulkarni

IntroductionThere has been a growing interest in the acquisition and sale of telehealth providers. While the COVID-19 pandemic may have laid the foundation, a recent wave of success for online compounding pharmacies producing weight loss drugs has enhanced the interest in telehealth companies. Such telehealth companies are focusing on “diseases du jour,” some of which have drawn negative attention from lawmakers over their potentially misleading advertising and prescribing practices.

Sep 17, 2024 | businesslawtoday.org | Darshan Kulkarni

There has been a notable uptick in clinical research sites being bought out by private equity and venture capital companies. This trend signifies the growing recognition of the value these sites hold, not just in terms of their operational capabilities, but also through the critical data they generate. However, for both buyers and sellers, there are significant considerations to keep in mind to navigate these transactions successfully and ethically.

Apr 1, 2024 | clinicalleader.com | Jenifer Ngo Waldrop |Darshan Kulkarni |Kerry Leyden |Caroline Potts

Exploring Tokenism In Clinical Trials For Rare Disease PatientsWhile recent efforts promote diversity in clinical studies, the lack of enforcement and tokenistic approaches risk leaving minorities behind. Delve into the urgency of addressing this crisis and building inclusivity for a healthier future for all.

Mar 4, 2024 | clinicalleader.com | Darshan Kulkarni

By Darshan Kulkarni, Pharm.D., MS, Esq., principal attorney, Kulkarni Law Firm, and host of Darshan Talks podcast The medical landscape is shifting away from the "one size fits all" approach, with the FDA paying more attention to the collection of race and ethnicity data and opining about enhancing the diversity of clinical trial populations.